405 related articles for article (PubMed ID: 24144415)
21. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
Murcia L; Carrilero B; Albajar Viñas P; Segovia M
Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
[No Abstract] [Full Text] [Related]
22. [Nifurtimox, a bright future for treatment of Chagas disease].
Wolf A; Boulliat C; Coillot C; Rouault M; Gaillard K; Beranger C; Oliver M
Med Trop (Mars); 2011 Apr; 71(2):131-3. PubMed ID: 21695868
[TBL] [Abstract][Full Text] [Related]
23. Drug Discovery for Paediatric Chagas Disease.
Thota S; Morel CM
Mini Rev Med Chem; 2018; 18(9):776-780. PubMed ID: 26202205
[TBL] [Abstract][Full Text] [Related]
24. The challenge of Chagas' disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi.
de Castro SL
Acta Trop; 1993 Apr; 53(2):83-98. PubMed ID: 8098901
[TBL] [Abstract][Full Text] [Related]
25. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host.
Maya JD; Cassels BK; Iturriaga-Vásquez P; Ferreira J; Faúndez M; Galanti N; Ferreira A; Morello A
Comp Biochem Physiol A Mol Integr Physiol; 2007 Apr; 146(4):601-20. PubMed ID: 16626984
[TBL] [Abstract][Full Text] [Related]
26. Effects of buthionine sulfoximine nifurtimox and benznidazole upon trypanothione and metallothionein proteins in Trypanosoma cruzi.
Maya JD; Rodríguez A; Pino L; Pabón A; Ferreira J; Pavani M; Repetto Y; Morello A
Biol Res; 2004; 37(1):61-9. PubMed ID: 15174306
[TBL] [Abstract][Full Text] [Related]
27. 5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
Cabrera E; Murguiondo MG; Arias MG; Arredondo C; Pintos C; Aguirre G; Fernández M; Basmadjián Y; Rosa R; Pacheco JP; Raymondo S; Di Maio R; González M; Cerecetto H
Eur J Med Chem; 2009 Oct; 44(10):3909-14. PubMed ID: 19446929
[TBL] [Abstract][Full Text] [Related]
28. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
Filardi LS; Brener Z
Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
[TBL] [Abstract][Full Text] [Related]
29. Drug discovery for chagas disease: A viewpoint.
Kratz JM
Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
[TBL] [Abstract][Full Text] [Related]
30. Trypanocidal effect of the benzyl ester of N-propyl oxamate: a bi-potential prodrug for the treatment of experimental Chagas disease.
Wong-Baeza C; Nogueda-Torres B; Serna M; Meza-Toledo S; Baeza I; Wong C
BMC Pharmacol Toxicol; 2015 Apr; 16():10. PubMed ID: 25896924
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of new potent 5-nitrofuryl derivatives as anti-Trypanosoma cruzi agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design.
Aguirre G; Cabrera E; Cerecetto H; Di Maio R; González M; Seoane G; Duffaut A; Denicola A; Gil MJ; Martínez-Merino V
Eur J Med Chem; 2004 May; 39(5):421-31. PubMed ID: 15110968
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
Vega MC; Rolón M; Montero-Torres A; Fonseca-Berzal C; Escario JA; Gómez-Barrio A; Gálvez J; Marrero-Ponce Y; Arán VJ
Eur J Med Chem; 2012 Dec; 58():214-27. PubMed ID: 23124218
[TBL] [Abstract][Full Text] [Related]
33. Trypanosoma cruzi: In vitro effect of aspirin with nifurtimox and benznidazole.
López-Muñoz R; Faúndez M; Klein S; Escanilla S; Torres G; Lee-Liu D; Ferreira J; Kemmerling U; Orellana M; Morello A; Ferreira A; Maya JD
Exp Parasitol; 2010 Feb; 124(2):167-71. PubMed ID: 19735656
[TBL] [Abstract][Full Text] [Related]
34. Novel polymorphs of the anti-Trypanosoma cruzi drug benznidazole.
Honorato SB; Mendonça JS; Boechat N; Oliveira AC; Mendes Filho J; Ellena J; Ayala AP
Spectrochim Acta A Mol Biomol Spectrosc; 2014 Jan; 118():389-94. PubMed ID: 24076454
[TBL] [Abstract][Full Text] [Related]
35. ESR, electrochemical, molecular modeling and biological evaluation of 4-substituted and 1,4-disubstituted 7-nitroquinoxalin-2-ones as potential anti-Trypanosoma cruzi agents.
Aguilera-Venegas B; Olea-Azar C; Norambuena E; Arán VJ; Mendizábal F; Lapier M; Maya JD; Kemmerling U; López-Muñoz R
Spectrochim Acta A Mol Biomol Spectrosc; 2011 Mar; 78(3):1004-12. PubMed ID: 21239218
[TBL] [Abstract][Full Text] [Related]
36. Structural analysis and molecular docking of trypanocidal aryloxy-quinones in trypanothione and glutathione reductases: a comparison with biochemical data.
Vera B; Vázquez K; Mascayano C; Tapia RA; Espinosa V; Soto-Delgado J; Salas CO; Paulino M
J Biomol Struct Dyn; 2017 Jun; 35(8):1785-1803. PubMed ID: 27232454
[TBL] [Abstract][Full Text] [Related]
37. Chagas disease: Present status of pathogenic mechanisms and chemotherapy.
Maya JD; Orellana M; Ferreira J; Kemmerling U; López-Muñoz R; Morello A
Biol Res; 2010; 43(3):323-31. PubMed ID: 21249304
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and 2D-QSAR studies of neolignan-based diaryl-tetrahydrofuran and -furan analogues with remarkable activity against Trypanosoma cruzi and assessment of the trypanothione reductase activity.
Hartmann AP; de Carvalho MR; Bernardes LSC; Moraes MH; de Melo EB; Lopes CD; Steindel M; da Silva JS; Carvalho I
Eur J Med Chem; 2017 Nov; 140():187-199. PubMed ID: 28926763
[TBL] [Abstract][Full Text] [Related]
39. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives.
Wilkinson SR; Bot C; Kelly JM; Hall BS
Curr Top Med Chem; 2011; 11(16):2072-84. PubMed ID: 21619510
[TBL] [Abstract][Full Text] [Related]
40. Trypanocidal drugs: mechanisms, resistance and new targets.
Wilkinson SR; Kelly JM
Expert Rev Mol Med; 2009 Oct; 11():e31. PubMed ID: 19863838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
